search
Back to results

Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens

Primary Purpose

Myopia

Status
Terminated
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
senfilcon A contact lens
investigational enfilcon A
Sponsored by
Coopervision, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myopia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Be at least 18 years of age as of the date of evaluation for the study.
  2. Not using any ocular medications
  3. Have a self-reported full eye examination within 2 years.
  4. Have:

    • read the Informed Consent
    • be given an explanation of the Informed Consent
    • indicate understanding of the Informed Consent
    • signed the Informed Consent document.
  5. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
  6. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses on a daily basis for at least 8 hours per day for at least one month prior to participation in the study.
  7. Possess wearable and visually functional eyeglasses.
  8. Be in good general health, based on his/her knowledge.
  9. Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 0.75 diopter of refractive astigmatism in order to have the best spherical equivalent power of -6.50 or less.
  10. Be willing to wear contact lenses in both eyes.
  11. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 (less than or equal to LogMAR 0.10) in each eye.
  12. Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye.

Exclusion Criteria:

  1. Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
  2. Any active participation in another one-day clinical trial within 7 days prior to this study or another dispensing trial within 30 days prior to this study.
  3. Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next month.
  4. Has a known sensitivity to ingredients used in the over the counter contact lens care approved for use in the study.
  5. Previous refractive surgery/anterior segment surgery; or current or previous orthokeratology treatment or irregular cornea.
  6. Is aphakic or pseudophakic.
  7. Unable to achieve a satisfactory fit with the lens designs used in the study
  8. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes.
  9. The need for topical ocular medications or any medication which might contradict contact lens wear or which would require the lenses to be removed during the day.
  10. The presence of clinically anterior segment infection, inflammations or abnormalities; such as iritis; or any infection of the eye, lids, or associated structures.
  11. A history of herpetic keratitis.
  12. A known history of corneal hypoesthesia (reduced corneal sensitivity) or active corneal ulcer, corneal infiltrates or fungal infection.
  13. A history of papillary conjunctivitis that has interfered with contact lens wear.
  14. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

    • Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > grade 2
    • Pterygium
    • Corneal scars within the visual axis
    • Corneal edema or corneal staining ≥ grade 2
    • Neovascularization or ghost vessels > 1.0 mm in from the limbus
    • Giant papillary conjunctivitis (GPC) of > grade 2.
    • Seborrheic eczema, seborrheic conjunctivitis or blepharitis

Sites / Locations

  • Clinical Research Center, University of California, Berkeley
  • University of Manchester

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

enfilcon A + senofilcon A

Arm Description

Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other

Outcomes

Primary Outcome Measures

Subjective Comfort Preference - Participants Preference Response
Subjective responses of participants administered by questionnaire and measured on a linear scale (0-100) measured at each visit.
Ocular Health
Ocular health determined by biomicroscopy recorded on a severity scale (0-4) for change from baseline over 30 days.

Secondary Outcome Measures

Investigator Surface Preference
Investigator Surface Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)
Investigator Fit Preference
Investigator Fit Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)

Full Information

First Posted
May 22, 2011
Last Updated
August 26, 2019
Sponsor
Coopervision, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01386008
Brief Title
Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens
Official Title
Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Terminated
Why Stopped
unexpected adverse events
Study Start Date
May 2011 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Coopervision, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the performance of the investigational CooperVision silicone hydrogel lens compared to a currently-marketed silicone hydrogel contact lens up to 30 days of daily lens wear.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
N/A
Enrollment
28 (Actual)

8. Arms, Groups, and Interventions

Arm Title
enfilcon A + senofilcon A
Arm Type
Other
Arm Description
Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other
Intervention Type
Device
Intervention Name(s)
senfilcon A contact lens
Intervention Description
senofilcon A spherical contact lens worn in a daily wear modality
Intervention Type
Device
Intervention Name(s)
investigational enfilcon A
Intervention Description
investigational enfilcon A, worn daily wear modality
Primary Outcome Measure Information:
Title
Subjective Comfort Preference - Participants Preference Response
Description
Subjective responses of participants administered by questionnaire and measured on a linear scale (0-100) measured at each visit.
Time Frame
V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)
Title
Ocular Health
Description
Ocular health determined by biomicroscopy recorded on a severity scale (0-4) for change from baseline over 30 days.
Time Frame
Change from baseline over 30 days measured at V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)
Secondary Outcome Measure Information:
Title
Investigator Surface Preference
Description
Investigator Surface Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)
Time Frame
V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)
Title
Investigator Fit Preference
Description
Investigator Fit Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)
Time Frame
V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Be at least 18 years of age as of the date of evaluation for the study. Not using any ocular medications Have a self-reported full eye examination within 2 years. Have: read the Informed Consent be given an explanation of the Informed Consent indicate understanding of the Informed Consent signed the Informed Consent document. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses on a daily basis for at least 8 hours per day for at least one month prior to participation in the study. Possess wearable and visually functional eyeglasses. Be in good general health, based on his/her knowledge. Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 0.75 diopter of refractive astigmatism in order to have the best spherical equivalent power of -6.50 or less. Be willing to wear contact lenses in both eyes. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 (less than or equal to LogMAR 0.10) in each eye. Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye. Exclusion Criteria: Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis. Any active participation in another one-day clinical trial within 7 days prior to this study or another dispensing trial within 30 days prior to this study. Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next month. Has a known sensitivity to ingredients used in the over the counter contact lens care approved for use in the study. Previous refractive surgery/anterior segment surgery; or current or previous orthokeratology treatment or irregular cornea. Is aphakic or pseudophakic. Unable to achieve a satisfactory fit with the lens designs used in the study Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes. The need for topical ocular medications or any medication which might contradict contact lens wear or which would require the lenses to be removed during the day. The presence of clinically anterior segment infection, inflammations or abnormalities; such as iritis; or any infection of the eye, lids, or associated structures. A history of herpetic keratitis. A known history of corneal hypoesthesia (reduced corneal sensitivity) or active corneal ulcer, corneal infiltrates or fungal infection. A history of papillary conjunctivitis that has interfered with contact lens wear. Slit lamp findings that would contraindicate contact lens wear, including but not limited to: Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > grade 2 Pterygium Corneal scars within the visual axis Corneal edema or corneal staining ≥ grade 2 Neovascularization or ghost vessels > 1.0 mm in from the limbus Giant papillary conjunctivitis (GPC) of > grade 2. Seborrheic eczema, seborrheic conjunctivitis or blepharitis
Facility Information:
Facility Name
Clinical Research Center, University of California, Berkeley
City
Berkeley
State/Province
California
ZIP/Postal Code
94704
Country
United States
Facility Name
University of Manchester
City
Manchester
ZIP/Postal Code
M13 9PL
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens

We'll reach out to this number within 24 hrs